Category: 137076-54-1

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

(2)1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid tri-tert-butyl (8.3 mg)In DMF (0.1 mL) and DIEA (10 [mu] L)A solution of HBTU (5.5 mg) in DMF (100 muL) was added, (N1) (4.6 mg) in DMF (200 muL) and DIEA (20 muL)And the mixture was stirred at room temperature for 1.5 hours. Water (100 muL) was added,Purification by preparative HPLC gave (N 2) (3.5 mg).

137076-54-1, The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; FUJIFILM Corporation; Fujifilm RI Pharma Co., Ltd.; Hirofumi, Fukunaga; Do En, Hiroyuki; Hino, Akihiro; Oshikiri, Shinobu; Chou, Rumpf; (131 pag.)JP2016/183151; (2016); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

The solids thus obtained were redissolved in DMF andsuccessively treated with HOBt (45.9 mg, 0.300 mmol), 2-(1,4,7,10-tetraaza-4,7,10-tris{[(tert-butyl)oxycarbonyl]methyl}-cyclododecyl)acetic acid (172 mg, 0.300 mmol), i-Pr2NEt(105 muL, 0.600 mmol) and HBTU (1 14 mg, 0.300 mmol) at 22 C.After 0.25 h, complete acylation was observed; only trace amounts ofregioisomeric and dimericproducts formed. The resulting solution was partitioned between EtOAcand H2O (50 mL each) with transfer to a separatory funnel. Thelayers separated and the aqueous layer washed with EtOAc (2 x 50 mL). The EtOAcsolution was further washed with 0.1 M NaOH (3 x 50 mL) and saturated aqueousNaCl (3 x 50 mL each), then dried over MgSO4, filtered andconcentrated in vacuo to a pale yellow oil that was used without furtherpurification in the subsequent deprotection step., 137076-54-1

137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Lantheus Medical Imaging, Inc.; Sesady, Richard Al; Harris, Thomas?D; Robinson, Simon P; Ruby, Richard J; Jijimon, Edward H; Yallamanchilli, Padmaja; Cosebio, David S; (97 pag.)KR101595324; (2016); B1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(1) To a solution of tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (24.8 mg) in DMF (0.2 mL) and DIEA (17 muL), a solution of HBTU (17.0 mg) in DMF (100 muL) was added, then the mixture was added to a solution of compound (L7) (13.1 mg) in DMF (200 muL) and DIEA (10 muL), and the resulting mixture was stirred at room temperature for 1 hour. Water (200 muL) was added thereto, and the mixture was purified by preparative HPLC to obtain compound (M1) (12.3 mg). LC/MS (SunFire) rt (min): 11.05 MS (ESI, m/z): 730.95 [M+2H]2+, 1459.05 [M-H]-

137076-54-1, The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; FUJIFILM Corporation; FUJIFILM RI PHARMA CO., LTD.; FUKUNAGA, Hirofumi; DOZONO, Hiroyuki; HINO, Akihiro; OSHIKIRI, Shinobu; NAGANO, Akio; (99 pag.)US2016/199520; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(11) To a solution of tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (25.1 mg) in DMF (150 muL) and DIEA (30 muL), a solution of HBTU (16.7 mg) in DMF (150 muL) was added, then the mixture was added to a solution of compound (Q10) (13.9 mg) in DMF (400 muL) and DIEA (20 muL), and the resulting mixture was stirred at room temperature for 45 minutes. Water (300 muL) was added thereto, and the mixture was purified by preparative HPLC to obtain compound (Q11) (11.1 mg). HPLC (SunFire) rt (min): 10.80 LC/MS (ACQUITY) rt (min): 1.24 MS (ESI, m/z): 1504.6 [M+H]+, 1502.6 [M-H]-, 137076-54-1

The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; FUJIFILM Corporation; FUJIFILM RI PHARMA CO., LTD.; FUKUNAGA, Hirofumi; DOZONO, Hiroyuki; HINO, Akihiro; OSHIKIRI, Shinobu; NAGANO, Akio; (99 pag.)US2016/199520; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

137076-54-1, To a solution of product 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid (572.7 mg, 1 mmol) in dry DMF (15 ml), amino-maleinnide 137 (483.3 mg, 1 mmol) was added with HATU (272 mg, 1 .4 mmol) and DIPEA (360 mul, 1.84 mmol). The mixture was stirred overnight at room temperature. After removing the solvent under the vacuum, the crude product was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 90:10) to give compound tri-tert-butyl 2,2′,2″-(10-(2-((2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate as a white foam (396 mg, 57 %). Rf : 0.3 (CH2Cl2/MeOH, 90:10). 1H NMR (300MHz, CDCl3) delta 8.30 (b, 1 H, NH), 6.86 (s,2H, H6′), 3.78-3.54 (br, 4H, H3′, H4′), 3.54 (br, 4H, H13, H1′), 3.48 (br, 4H, H8), 3.09-2.99 (m, 8H, H2, H3), 2.97-2.86 (m, 8H, H5, H6), 1 .46 (s, 18H, H12), 1 .45 (s, 9H, H17). 13C NMR (75MHz, CDCl3) delta 171 .6 (C2′), 171 .0 (C5′), 170.4 (C9, C14), 134.2 (C6′), 81 .5 (C16), 81 .3 (C11), 57.8 (C1′), 55.7-55.2 (C8, C13), 54.1 – 51 .5 (C2, C3), 51 .0-48.9 (C5, C6), 38.0 (C4′), 32.7 (C3′), 27.8 (C17), 27.6 (C12). MS (ESI) : m/z 695 [M + H]+.

As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Patent; INSTITUT CURIE; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6); FLORENT, Jean-Claude; AIT SARKOUH, Rafik; JOHANNES, Ludger; SCHMIDT, Frederic; OBERLEITNER, Birgit; DRANSART, Estelle; SEMETEY, Vincent; WO2014/86942; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(7) To a mixture of compound (K6) (84.3 mg), tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (60.7 mg), DMF (1 mL), and DIEA (50 muL), HBTU (40.2 mg) was added, and the resulting mixture was stirred at room temperature for 30 minutes. Water (1 mL), methanol (0.5 mL), and formic acid (200 muL) were added thereto, and the mixture was purified by preparative HPLC to obtain compound (K7) (61.9 mg). LC/MS (ACQUITY) rt (min): 1.12 MS (ESI, m/z): 677.4 [M+2H]2+, 1351.3 [M-H]-, 137076-54-1

137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; FUJIFILM Corporation; FUJIFILM RI PHARMA CO., LTD.; FUKUNAGA, Hirofumi; DOZONO, Hiroyuki; HINO, Akihiro; OSHIKIRI, Shinobu; NAGANO, Akio; (99 pag.)US2016/199520; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

To a DOTA-tra-tBu ester (28.6 mg, 0.05 mmol) in 2 mL DMF, DIPEA (24.8 mg, 0.192 mmol), HOBt (16.2 mg, 0.096 mmol), 43 (50 mg, 0.048 mmol) and EDCI (18.2 mg, 0.096 mmol) were added at 0 C. The mixture was stirred at room temperature for overnight, then 15 mL EtOAc was added to above solution. It was then washed with H20 (5 mL x 2) and brine (5 mL), dried over MgS04, and filtered. The filtrate was concentrated, and the residue was purified by FC (DCM/MeOH/NH4OH = 95/5/0.5) to give 43 as a colorless oil (yield: 26 mg, 35.6%): HRMS calcd. for C39H64N5Oio (1/2M + H)+: 762.4653, found 762.4787., 137076-54-1

137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; FIVE ELEVEN PHARMA INC.; KUNG, Hank F.; PLOESSL, Karl; CHOI, Seok Rye; ZHA, Zhihao; WU, Zehui; (131 pag.)WO2017/116994; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1.2 equivalents of HATU were sequentially added to the DMF solution in which the compound 6 was dissolved at 0 C, 2 equivalents of DIPEA and 0.9 equivalents of compound 7, the reaction was naturally warmed to room temperature. After completion of the reaction, it was quenched with water and extracted with ethyl acetate. The organic phase obtained by extraction was dried over anhydrous sodium sulfate and then evaporated. The residue was purified by silica gel column chromatography to give Compound 8., 137076-54-1

As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Patent; Beijing University Shenzhen Sheng Yuan; Li Zhicheng; Ye Weijian; Huang Junrong; Liang Zhenhao; (16 pag.)CN108358952; (2018); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI